Figure 1a:

Comparative Clinical effectiveness Incremental costutility (cost per QALY)

Other benefits or disadvantages (i)

(i) "Does treating patients with Treatment X offer one or more of the following other benefits or disadvantages?"

disadvantages?"
-Benefit/ disadvantage 1: Yes/No
-Benefit/ disadvantage 2: Yes/No
-Benefit/ disadvantage 3: Yes/No
-Benefit/ disadvantage 4: Yes/No
-Benefit/ disadvantage 5: Yes/No
-Benefit/ disadvantage 6: Yes/No

-Benefit/ disadvantage 7: Yes/No

Contextual considerations (ii)

- (ii) "Are any of the following contextual considerations important in assessing Treatment's X long-term value for money?"
- -Consideration 1: Yes/No -Consideration 2: Yes/No -Consideration 3: Yes/No -Consideration 4: Yes/No
- -Consideration 5: Yes/No -Consideration 6: Yes/No

effectiveness and incremental
cost-effectiveness, and
considering other benefits,
disadvantages, and
contextual considerations,

what is the long-term value for money of Treatment X versus Treatment Y?"

Long-Term

Value for

Money (iii)

(iii) "Given the available

evidence on comparative

-Low/ Intermediate/ High

Potential budget impact

Value-Based Price Benchmarks

Short-Term Value for Money

Figure 1b:

Comparative Clinical effectiveness Incremental costutility (cost per QALY)

Other benefits or disadvantages and contextual considerations (i, ii)

(i, ii)"Does treating patients with Treatment X offer one or more of the following other benefits or disadvantages and contextual considerations?"

- -Benefit/ disadvantage 1: Lower/ Intermediate/ Higher Value -Benefit/ disadvantage 2: Lower/ Intermediate/ Higher Value
- -Benefit/ disadvantage 3: Lower/ Intermediate/ Higher Value -Benefit/ disadvantage 4: Lower/ Intermediate/ Higher Value
- -Benefit/ disadvantage 5: Lower/ Intermediate/ Higher Value -Benefit/ disadvantage 6: Lower/ Intermediate/ Higher Value
- -Consideration 1: Lower/ Intermediate/ Higher Value -Consideration 2: Lower/ Intermediate/ Higher Value
- -Consideration 2: Lower/ Intermediate/ Higher Value
 -Consideration 3: Lower/ Intermediate/ Higher Value
- -Other: Lower/ Intermediate/ Higher Value
 - Data atial land

Long-Term Value for Money (iii)

(iii) "Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of Treatment X versus Treatment Y?"
-Low/ Intermediate/ High

Health-Benefit Price Benchmarks

Potential budget impact

Short-Term Value for Money

Figure 1c:

Comparative Clinical effectiveness Incremental costutility (cost per QALY)

Other benefits or disadvantages and contextual considerations (i, ii)

(i, ii) Step 1 - Valuation of performance: Score the performance of Treatment X against other benefits or disadvantages and contextual considerations, e.g. indirectly by eliciting value functions that correlate performance on the relevant benefits and considerations with a value scale that ranges from 0 to 100

Step 2 - Valuation of trade-offs: Weight the relative importance of the relevant other benefits or disadvantages and contextual considerations for Treatment's X long-term value for money, e.g. indirectly by swing weighting using the ICER lower value and higher value Likert-scale benchmarks

Potential budget impact

Long-Term Value for Money (iii)

(iii) Step 3 - Aggregation: Combine together Treatment's X value scores and their relative weights to derive an overall weighted value score

Step 4 – Threshold adjustment: Depending on the relative contribution of other benefits and considerations to Treatment's X overall value, expand the baseline \$100K threshold accordingly up to \$150K

Short-Term

Health-Benefit Price Benchmarks